Market Research Logo

Global Biological Safety Testing Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

Global Biological Safety Testing Market Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

Biological safety testing is a method that involves testing the safety of all pharmaceuticals such as vaccines and medicinal drugs. The global biological safety testing market is expected to grow at the CAGR of 13% during the forecast period of 2016-2023. Drug launches in recent years mainly contributes to the growth of the global biological safety testing market during the forecast period. However, high healthcare and investment cost and lack of regulatory framework are the factors restraining the growth of the global biological safety testing market during the forecast period.

Geographically, North America accounted for the largest market share in terms of revenue for the biological safety testing market in 2016 followed by Europe. North America is expected to dominate the market during the forecast period. The growth in the region is witnessed owing to adoption of biotechnology in cancer research. Asia Pacific is expected to be the fastest growing region for biological safety testing market during the forecast period due to presence of emerging economies in the region such as China, India and South Korea.

The growth in global biological safety testing market is also influenced by the presence of major players such as Thermo Fisher Scientific Inc. (U.S.), SGS SA (Switzerland), Lonza Group Ltd. (Switzerland), Merck KGAA (Germany), Wuxi Apptec (China) etc. product launches, partnetships, mergers & acquisitions etc. are some of the crucial strategies which are adopted by the major players to gain competitive advantage.

Global biological safety testing market report covers segmentation analysis of product, test and applications. Report further covers segments of product which include instruments, kits and reagents and services. Kits and reagents are expected to dominate the segment during the forecast period. The dominance of the segment is attributed to its high popularity and launch of more efficient technologies during the forecast period. Moreover, the test types in biological safety testing are divided as adventitious agent detection test, bio burden test, cell line authentication and characterization test, endo toxin test, residual host contamination detection test, sterility test and other tests. The endo toxin tests and sterility tests segment is expected to dominate the market during the forecast period owing to increasing awareness and implication of stringent regulations. Furthermore, the applications of biological safety testing include blood and blood related products testing, cellular and gene therapy, stem cell research, tissue and tissue related products testing and vaccine and therapeutic development. Vaccine and therapeutic development is expected to dominate the market during the forecast period owing to increasing investments in vaccine development.

Please note: The delivery time for the electronic version of this report is between 1-3 business days to allow the preparation of an updated version prior to dispatch.


1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY
2. MARKET OVERVIEW
2.1. BIOLOGICAL SAFETY TESTING MARKET: EVOLUTION & TRANSITION
2.2. MARKET DEFINITION & SCOPE
2.3. INDUSTRY STRUCTURE
2.4. REGULATORY FRAMEWORK
2.5. TOTAL MARKET ANALYSIS
2.5.1. TOP 5 FINDINGS
2.5.2. TOP 5 OPPORTUNITY MARKETS
2.5.3. TOP 5 COMPANIES
2.5.4. TOP 3 COMPETITIVE STRATEGIES
2.6. ESTIMATION ANALYSIS
2.7. STRATEGIC ANALYSIS
2.7.1. INVESTMENT VS. ADOPTION MODEL
2.7.2. 360-DEGREE INDUSTRY ANALYSIS
2.7.3. PORTERS 5 FORCE MODEL
2.7.4. SEE-SAW ANALYSIS
2.7.5. CONSUMER ANALYSIS AND KEY BUYING CRITERIA
2.8. COMPETITIVE ANALYSIS
2.8.1. KEY STRATEGIES & ANALYSIS
2.8.2. MARKET SHARE ANALYSIS AND TOP COMPANY ANALYSIS
2.9. STRATEGIC RECOMMENDATIONS & KEY CONCLUSIONS
2.9.1. INVESTMENT OPPORTUNITIES BY REGIONS
2.9.2. OPPORTUNITIES IN EMERGING APPLICATIONS
2.9.3. INVESTMENT OPPORTUNITY IN FASTEST GROWING SEGMENT
3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. INCREASING PREVALANCE OF CHRONIC DESEASES GLOBALLY
3.1.2. INCREASE IN NUMBER OF DRUG LAUNCHES
3.1.3. GROWTH OF BIOTECHNOLOGY AND BIOPHARMACEUTICALS INDUSTRIES
3.1.4. R & D INVESTMENTS IN LIFE SCIENCE
3.1.5. STRINGENT REGULATIONS ISSUED BY HEALTHCARE ORGANIZATIONS
3.2. MARKET RESTRAINTS
3.2.1. HIGH HEALTHCARE AND INVESTMENT COSTS
3.2.2. LACK OF REGULATORY FRAMEWORK
3.3. MARKET OPPORTUNITIES
3.3.1. INCREASING PHARMACEUTICAL OUTSOURCING
3.3.2. INCREASING APPLICATIONS IN THERAPEUTICS AND EXPANSION IN ASIA PACIFIC
3.4. MARKET CHALLENGES
3.4.1. LACK OF SKILLED PROFESSIONALS
4. MARKET SEGMENTATION
4.1.1. BIOLOGICAL SAFETY TESTING MARKET BY PRODUCT
4.1.2. MARKET DEFINITION AND SCOPE
4.1.3. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.1.4. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.1.5. OPPORTUNITY MATRIX
4.1.6. MARKET SEGMENTATION
4.1.6.1. GLOBAL INSTRUMENTS MARKET
4.1.6.1.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.1.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.1.3. TOP PLAYERS & KEY PRODUCTS
4.1.6.1.4. KEY CONCLUSIONS
4.1.6.2. GLOBAL KITS AND REAGENTS MARKET
4.1.6.2.1. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.2.2. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.2.3. TOP PLAYERS & KEY PRODUCTS
4.1.6.2.4. KEY CONCLUSIONS
4.1.6.3. GLOBAL SERVICES MARKET
4.1.6.3.1. APPLICATION
4.1.6.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.1.6.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.1.6.3.4. TOP PLAYERS & KEY PRODUCTS
4.1.6.3.5. KEY CONCLUSIONS
4.2. BIOLOGICAL SAFETY TESTING MARKET BY TEST TYPE
4.2.1. MARKET DEFINITION AND SCOPE
4.2.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.2.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.2.4. OPPORTUNITY MATRIX
4.2.5. MARKET SEGMENTATION
4.2.5.1. GLOBAL ADVENTITIOUS AGENT DETECTION TESTS MARKET
4.2.5.1.1. APPLICATION
4.2.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.1.5. KEY CONCLUSIONS
4.2.5.2. GLOBAL BIOBURDEN TESTS MARKET
4.2.5.2.1. APPLICATION
4.2.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.2.5. KEY CONCLUSIONS
4.2.5.3. GLOBAL CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS MARKET
4.2.5.3.1. APPLICATION
4.2.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.3.5. KEY CONCLUSIONS
4.2.5.4. GLOBAL ENDOTOXIN TESTS MARKET
4.2.5.4.1. APPLICATION
4.2.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.4.5. KEY CONCLUSIONS
4.2.5.5. GLOBAL RESIDUAL HOST CONTAMINATION DETECTION TESTS MARKET
4.2.5.5.1. APPLICATION
4.2.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.5.5. KEY CONCLUSIONS
4.2.5.6. GLOBAL STERILITY TESTS MARKET
4.2.5.6.1. APPLICATION
4.2.5.6.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.6.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.6.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.6.5. KEY CONCLUSIONS
4.2.5.7. GLOBAL OTHERS MARKET
4.2.5.7.1. APPLICATION
4.2.5.7.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.2.5.7.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.2.5.7.4. TOP PLAYERS & KEY PRODUCTS
4.2.5.7.5. KEY CONCLUSIONS
4.3. BIOLOGICAL SAFETY TESTING MARKET BY APPLICATION
4.3.1. MARKET DEFINITION AND SCOPE
4.3.2. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
4.3.3. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
4.3.4. OPPORTUNITY MATRIX
4.3.5. MARKET SEGMENTATION
4.3.5.1. GLOBAL BLOOD AND BLOOD RELATED PRODUCTS TESTING MARKET
4.3.5.1.1. APPLICATION
4.3.5.1.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.1.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.1.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.1.5. KEY CONCLUSIONS
4.3.5.2. GLOBAL CELLULAR AND GENE THERAPY MARKET
4.3.5.2.1. APPLICATION
4.3.5.2.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.2.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.2.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.2.5. KEY CONCLUSIONS
4.3.5.3. GLOBAL STEM CELL RESEARCH MARKET
4.3.5.3.1. APPLICATION
4.3.5.3.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.3.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.3.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.3.5. KEY CONCLUSIONS
4.3.5.4. GLOBAL TISSUE AND TISSUE RELATED PRODUCTS TESTING MARKET
4.3.5.4.1. APPLICATION
4.3.5.4.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.4.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.4.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.4.5. KEY CONCLUSIONS
4.3.5.5. GLOBAL VACCINE AND THERAPEUTICS DEVELOPMENT MARKET
4.3.5.5.1. APPLICATION
4.3.5.5.2. ADOPTION SCENARIO & MARKET DETERMINANTS
4.3.5.5.3. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
4.3.5.5.4. TOP PLAYERS & KEY PRODUCTS
4.3.5.5.5. KEY CONCLUSIONS
5. COMPETITIVE LANDSCAPE
5.1. KEY STRATEGIES
5.1.1. LIST OF MERGERS AND ACQUISITION
5.1.2. LIST OF JOINT VENTURES
5.1.3. LIST OF PRODUCT LAUNCHES
5.1.4. LIST OF PARTNERSHIPS
6. GEOGRAPHICAL ANALYSIS
6.1. DECISION SUPPORT DATABASE & ESTIMATION METHODOLOGY
6.2. COMPARATIVE ANALYSIS ACROSS MARKET SEGMENTS
6.3. OPPORTUNITY MATRIX
6.4. GLOBAL BIOLOGICAL SAFETY TESTING MARKET BY REGION 2014-2023 ($ MILLION)
6.4.1. NORTH AMERICA
6.4.1.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.1.2. TOP COUNTRY ANALYSIS
6.4.1.2.1. U.S.
6.4.1.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.1.3. KEY CONCLUSIONS
6.4.1.2.2. CANADA
6.4.1.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.1.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.1.2.2.3. KEY CONCLUSIONS
6.4.2. EUROPE
6.4.2.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.2.2. TOP COUNTRY ANALYSIS
6.4.2.2.1. UK
6.4.2.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.1.3. KEY CONCLUSIONS
6.4.2.2.2. FRANCE
6.4.2.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.2.3. KEY CONCLUSIONS
6.4.2.2.3. GERMANY
6.4.2.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.3.3. KEY CONCLUSIONS
6.4.2.2.4. SPAIN
6.4.2.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.4.3. KEY CONCLUSIONS
6.4.2.2.5. REST OF EUROPE
6.4.2.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.2.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.2.2.5.3. KEY CONCLUSIONS
6.4.3. ASIA PACIFIC
6.4.3.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.3.2. TOP COUNTRY ANALYSIS
6.4.3.2.1. CHINA
6.4.3.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.1.3. KEY CONCLUSIONS
6.4.3.2.2. INDIA
6.4.3.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.2.3. KEY CONCLUSIONS
6.4.3.2.3. JAPAN
6.4.3.2.3.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.3.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.3.3. KEY CONCLUSIONS
6.4.3.2.4. AUSTRALIA
6.4.3.2.4.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.4.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.4.3. KEY CONCLUSIONS
6.4.3.2.5. REST OF ASIA PACIFIC
6.4.3.2.5.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.3.2.5.2. TOP PLAYERS & KEY PRODUCTS
6.4.3.2.5.3. KEY CONCLUSIONS
6.4.4. ROW
6.4.4.1. INDUSTRY ANALYSIS 2014-2023 ($ MILLION)
6.4.4.2. TOP COUNTRY ANALYSIS
6.4.4.2.1. LATIN AMERICA
6.4.4.2.1.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.1.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.1.3. KEY CONCLUSIONS
6.4.4.2.2. MIDDLE EAST & AFRICA
6.4.4.2.2.1. MARKET ESTIMATIONS AND FORECASTS 2014-2023 ($ MILLION)
6.4.4.2.2.2. TOP PLAYERS & KEY PRODUCTS
6.4.4.2.2.3. KEY CONCLUSIONS
7. COMPANY PROFILES
7.1. LONZA GROUP LTD. (SWITZERLAND)
7.1.1. OVERVIEW
7.1.2. PRODUCT PORTFOLIO
7.1.3. KEY INNOVATION SECTOR
7.1.4. STRATEGIC INITIATIVES
7.1.5. SCOT ANALYSIS
7.1.6. STRATEGIC ANALYSIS
7.2. CHARLES RIVER LABORATORIES (U.S.)
7.2.1. OVERVIEW
7.2.2. PRODUCT PORTFOLIO
7.2.3. KEY INNOVATION SECTOR
7.2.4. STRATEGIC INITIATIVES
7.2.5. SCOT ANALYSIS
7.2.6. STRATEGIC ANALYSIS
7.3. MERCK KGAA (GERMANY)
7.3.1. OVERVIEW
7.3.2. PRODUCT PORTFOLIO
7.3.3. KEY INNOVATION SECTOR
7.3.4. STRATEGIC INITIATIVES
7.3.5. SCOT ANALYSIS
7.3.6. STRATEGIC ANALYSIS
7.4. SGS SA (SWITZERLAND)
7.4.1. OVERVIEW
7.4.2. PRODUCT PORTFOLIO
7.4.3. KEY INNOVATION SECTOR
7.4.4. STRATEGIC INITIATIVES
7.4.5. SCOT ANALYSIS
7.4.6. STRATEGIC ANALYSIS
7.5. WUXI APPTEC (CHINA)
7.5.1. OVERVIEW
7.5.2. PRODUCT PORTFOLIO
7.5.3. KEY INNOVATION SECTOR
7.5.4. STRATEGIC INITIATIVES
7.5.5. SCOT ANALYSIS
7.5.6. STRATEGIC ANALYSIS
7.6. THERMO FISHER SCIENTIFIC INC. (U.S.)
7.6.1. OVERVIEW
7.6.2. PRODUCT PORTFOLIO
7.6.3. KEY INNOVATION SECTOR
7.6.4. STRATEGIC INITIATIVES
7.6.5. SCOT ANALYSIS
7.6.6. STRATEGIC ANALYSIS
7.7. SARTORIUS AG (GERMANY)
7.7.1. OVERVIEW
7.7.2. PRODUCT PORTFOLIO
7.7.3. KEY INNOVATION SECTOR
7.7.4. STRATEGIC INITIATIVES
7.7.5. SCOT ANALYSIS
7.7.6. STRATEGIC ANALYSIS
7.8. CYTOVANCE BIOLOGICS INC. (U.S.)
7.8.1. OVERVIEW
7.8.2. PRODUCT PORTFOLIO
7.8.3. KEY INNOVATION SECTOR
7.8.4. STRATEGIC INITIATIVES
7.8.5. SCOT ANALYSIS
7.8.6. STRATEGIC ANALYSIS
7.9. PACE ANALYTICAL SERVICES INC. (U.S.)
7.9.1. OVERVIEW
7.9.2. PRODUCT PORTFOLIO
7.9.3. KEY INNOVATION SECTOR
7.9.4. STRATEGIC INITIATIVES
7.9.5. SCOT ANALYSIS
7.9.6. STRATEGIC ANALYSIS
7.10. TOXIKON CORPORATION (U.S.)
7.10.1. OVERVIEW
7.10.2. PRODUCT PORTFOLIO
7.10.3. KEY INNOVATION SECTOR
7.10.4. STRATEGIC INITIATIVES
7.10.5. SCOT ANALYSIS
7.10.6. STRATEGIC ANALYSIS
7.11. AVANCE BIOSCIENCES (U.S.)
7.11.1. OVERVIEW
7.11.2. PRODUCT PORTFOLIO
7.11.3. KEY INNOVATION SECTOR
7.11.4. STRATEGIC INITIATIVES
7.11.5. SCOT ANALYSIS
7.11.6. STRATEGIC ANALYSIS
7.12. NUAIRE (U.S.)
7.12.1. OVERVIEW
7.12.2. PRODUCT PORTFOLIO
7.12.3. KEY INNOVATION SECTOR
7.12.4. STRATEGIC INITIATIVES
7.12.5. SCOT ANALYSIS
7.12.6. STRATEGIC ANALYSIS
7.13. PARAGON BIOSERVICES INC. (U.S.)
7.13.1. OVERVIEW
7.13.2. PRODUCT PORTFOLIO
7.13.3. KEY INNOVATION SECTOR
7.13.4. STRATEGIC INITIATIVES
7.13.5. SCOT ANALYSIS
7.13.6. STRATEGIC ANALYSIS
7.14. NORDIC SCIENTIFIC AND NATURAL SOLUTIONS AB (SWEDEN)
7.14.1. OVERVIEW
7.14.2. PRODUCT PORTFOLIO
7.14.3. KEY INNOVATION SECTOR
7.14.4. STRATEGIC INITIATIVES
7.14.5. SCOT ANALYSIS
7.14.6. STRATEGIC ANALYSIS
7.15. SOURCE BIOSCIENCE (U.K.)
7.15.1. OVERVIEW
7.15.2. PRODUCT PORTFOLIO
7.15.3. KEY INNOVATION SECTOR
7.15.4. STRATEGIC INITIATIVES
7.15.5. SCOT ANALYSIS
7.15.6. STRATEGIC ANALYSIS
LIST OF TABLES
GLOBAL BIOLOGICAL SAFETY TESTING MARKET BY PRODUCT ($ MILLION)
GLOBAL INSTRUMENTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL KITS AND REAGENTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL SERVICES MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL BIOLOGICAL SAFETY TESTING MARKET BY TEST TYPE ($ MILLION)
GLOBAL ADVENTITIOUS AGENT DETECTION TESTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL BIOBURDEN TESTS FORENSICS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL ENDOTOXIN TESTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL RESIDUAL HOST CONTAMINATION DETECTION TESTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL STERLITY TESTS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL OTHERS MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL BIOLOGICAL SAFETY TESTING MARKET BY APPLICATION ($ MILLION)
GLOBAL BLOOD AND BLOOD RELATED PRODUCTS TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL CELLULAR AND GENE THERAPY MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL STEM CELL RESEARCH MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL TISSUE AND TISSUE RELATED PRODUCTS TESTING MARKET BY GEOGRAPHY ($ MILLION)
GLOBAL VACCINE AND THERAPEUTICS DEVELOPMENT MARKET BY GEOGRAPHY ($ MILLION)
NORTH AMERICA BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
EUROPE BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
ASIA PACIFIC BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
REST OF THE WORLD BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
LIST OF FIGURES
GLOBAL BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
GLOBAL INSTRUMENTS MARKET ($ MILLION)
GLOBAL KITS AND REAGENTS MARKET ($ MILLION)
GLOBAL SERVICES MARKET ($ MILLION)
GLOBAL ADVENTITIOUS AGENT DETECTION TESTS MARKET ($ MILLION)
GLOBAL BIOBURDEN TESTS FORENSICS MARKET ($ MILLION)
GLOBAL CELL LINE AUTHENTICATION AND CHARACTERIZATION TESTS MARKET ($ MILLION)
GLOBAL ENDOTOXIN TESTS MARKET ($ MILLION)
GLOBAL RESIDUAL HOST CONTAMINATION DETECTION TESTS MARKET ($ MILLION)
GLOBAL STERLITY TESTS MARKET ($ MILLION)
GLOBAL OTHERS MARKET ($ MILLION)
GLOBAL BLOOD AND BLOOD RELATED PRODUCTS TESTING MARKET ($ MILLION)
GLOBAL CELLULAR AND GENE THERAPY MARKET ($ MILLION)
GLOBAL STEM CELL RESEARCH MARKET ($ MILLION)
GLOBAL TISSUE AND TISSUE RELATED PRODUCTS TESTING MARKET ($ MILLION)
GLOBAL VACCINE AND THERAPEUTICS DEVELOPMENT MARKET ($ MILLION)
UNITED STATES (U.S.) BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
CANADA BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
UNITED KINGDOM (UK) BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
FRANCE BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
GERMANY BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
SPAIN BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
ROE BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
INDIA BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
CHINA BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
JAPAN BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
AUSTRALIA BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
ROAPAC BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
LATIN AMERICA BIOLOGICAL SAFETY TESTING MARKET ($ MILLION)
MENA BIOLOGICAL SAFETY TESTING MARKET 2014-2023 ($ MILLION)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report